Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zyclara and PDT for Actinic Keratosis
NCT01203878Phase 4Terminated
- Sponsor
- Tennessee Clinical Research Center
- Start
- Sep 2010
- Primary completion
- Nov 2011
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imiquimod in actinic keratosis (AK), sponsored by Tennessee Clinical Research Center. Primary endpoint: Actinic Keratosis Count at 18 weeks. Started Sep 2010; status: terminated.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01203878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203878.